Privosegtor (ACT-01)

About Oculis Holding AG

Oculis is a clinical-stage biotech on a mission to save sight and improve eye care through visionary innovation in topical drug delivery. The company has built a highly differentiated late-stage pipeline anchored by three core assets: OCS-01 for DME, Licaminlimab for dry eye disease, and Privosegtor for neuro-ophthalmic conditions like optic neuritis. Its strategy leverages proprietary technology platforms to address vast unmet medical needs in ophthalmology, transitioning key programs into Phase 3 trials following a successful U.S. IPO in 2023 which provided capital to advance its ambitious clinical agenda.

About Oculis Holding AG

Oculis is a clinical-stage biotech on a mission to save sight and improve eye care through visionary innovation in topical drug delivery. The company has built a highly differentiated late-stage pipeline anchored by three core assets: OCS-01 for DME, Licaminlimab for dry eye disease, and Privosegtor for neuro-ophthalmic conditions like optic neuritis. Its strategy leverages proprietary technology platforms to address vast unmet medical needs in ophthalmology, transitioning key programs into Phase 3 trials following a successful U.S. IPO in 2023 which provided capital to advance its ambitious clinical agenda.

Therapeutic Areas

Other Optic Neuritis Drugs